Compulsory licensing of pharmaceuticals during public health crisis: a TRIPS framework analysis. [PDF]
Li Z, Guo P.
europepmc +1 more source
The Role of Calcitonin Gene‐Related Peptide in High‐Altitude Headache: A Prospective Field Study
ABSTRACT Objective High‐altitude headache (HAH) is a common neurological condition associated with rapid ascent to high altitude. The pathophysiological mechanisms underlying HAH remain incompletely understood. Calcitonin gene‐related peptide (CGRP), a neuropeptide implicated in migraine pathophysiology, may play a key role in the pathophysiology of ...
Roman Schniepp +4 more
wiley +1 more source
Avon Longitudinal Study of Parents and Children (ALSPAC) summary education attainment values in the offspring generation. [PDF]
Walsh EI, Mumme M, Northstone K.
europepmc +1 more source
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Dollars and dilemmas: lenacapavir's pricing, patents, and the path to affordability. [PDF]
Adepoju VA, Abdulrahim A.
europepmc +1 more source
Designing the global vaccine supply chain: balancing intellectual property rights with post COVID-19 vaccine equity. [PDF]
Park SP, Lee HJ, Yu Y, Lee EYJ, Park YS.
europepmc +1 more source
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi +9 more
wiley +1 more source
From proposal to compromise: the TRIPS waiver debate and the crisis of WTO decision-making. [PDF]
Syam N, Abbas MZ.
europepmc +1 more source
Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan
ABSTRACT Objective There are limited real‐world data regarding the safety and effectiveness of onasemnogene abeparvovec (OA; Zolgensma) infusion, a one‐time gene replacement therapy, for Japanese patients with spinal muscular atrophy (SMA). We aimed to improve understanding of the real‐world outcomes for OA in Japan.
Kayoko Saito +8 more
wiley +1 more source
The Price of Silence: What 2 Decades of Policy-and a Pandemic-Have Taken From Spine Surgeons: An Independent Analysis. [PDF]
Lorio MP, Lewandrowski KU.
europepmc +1 more source

